Related Experiment Video
Updated: Jan 13, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Does metabolic dysfunction-associated steatotic liver disease affect the ocular circulation?
Nihat Aydın1, Mustafa Capraz2, Burcu Akman3
1Department of Ophthalmology, Amasya University, Sabuncuoğlu Şerefeddin Training and Research Hospital, Amasya, Turkey.
Purpose:
To evaluate the choroidal thickness (CT), central retinal artery (CRA), ophthalmic artery (OA), internal carotid artery (ICA) and common carotid artery (CCA) hemodynamic parameters and the carotid intima-media thickness (CIMT) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
Methods:
This prospective study included 98 MASLD patients and 30 healthy controls. MASLD patients were classified into three stages via liver ultrasonography.
Results:
CT was significantly decreased at all measured points in Stage 2 and Stage 3 MASLD patients versus controls and at subfoveal and nasal (500-1000-1500 µm) points in Stage 3 compared to Stage 1(all p < 0.05). A significant relationship was observed between CT and age, MASLD stage, and GGT levels. OA peak sistolik velocity (PSV), ICA PSV, enddiastolic velocity (EDV), and CCA EDV values were significantly lower in Stage 3 compared to the control group and Stage 1 while the ICA PSV and CCA EDV values were significantly lower in Stage 3 compared to Stage 2 (all p < 0.05). The CCA resistive index (RI) and pulsatile index (PI) were significantly higher in Stage 3 than in the control group and Stage 1 as with the CCA PI value in Stage 3 compared to Stage 2 (p = 0.026, p = 0.035, p = 0.011, p = 0.014, p = 0.022, respectively). CIMT was significantly higher in Stage 3 than in controls (p = 0.005).
Conclusions:
MASLD affects ocular vascular structures and may be associated with an increased risk of ocular pathologies.
More Related Videos
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Glaucoma: Overview